

## **Louisiana Fee-for-Service (FFS) Medicaid Self-Injected Epinephrine**

### **Approval criteria for non-preferred agents:**

The following is required for both initial and reauthorization requests:

- The medication is being prescribed for the indication of the emergency treatment of allergic reactions (Type I) including anaphylaxis; AND
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc; AND
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; AND
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended: AND
  - The recipient has no inappropriate concomitant drug therapies or disease states; AND
- The recipient has had a treatment failure with at least one preferred product; OR
- The recipient has had an intolerable side effect to at least one preferred product; OR
- The recipient has a documented contraindication to all of the preferred products which are appropriate for the condition being treated; OR
- There is no preferred product appropriate to use for the condition being treated.

**Duration of authorization approval, both initial and reauthorization: 12 months**

**Table 1. Quantity Limits for Preferred and Non-Preferred Agents\***

<b>Medication</b>	<b>Quantity Limit</b>
Epipen® (Brand and Generic)	4 boxes of 2 syringes (8 syringes total)
Epipen Jr® (Brand and Generic)	per rolling 365 days

\*Point-of-Sale (POS) override of the quantity limit is available at the pharmacy.

### **Reference**

EpiPen®/EpiPen Jr® (epinephrine) [package insert]. Morgantown, WV: Mylan Specialty LP; May 2016. Retrieved from  
[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/019430s061lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019430s061lbl.pdf)